BIOGEN lobbying for BIOGEN

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 19, 2026

Expenses

$770,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

AARON BILL New on this filing

Previously held: U.S. House of Representatives-Staff assistant, Associate Counsel, Policy Fellow, Legislative Counsel, Legislative Director, Legislative Assistant- 9/06- 8/08 and 4/14 - 11/23.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 7

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
Veterans Affairs, Dept of (VA)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
S 864
HELP Copays Act

Lobbying activity 5

Medicare/Medicaid

Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.

Pharmacy

Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill.

Taxation/Internal Revenue Code

Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property, no related bills

Health Issues

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share